Lawrence M. Alleva, Director at Adaptimmune Therapeutics PLC (ADAP), bought 12,600 shares at $0.79 ($10K) on 2021-06-01, disclosed to the SEC on 2021-06-03.
Open-market purchase of $10k ADAP by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| GRTX | BUY | 2021-06-03 | $35K | — | Filing → |
| GRTX | BUY | 2020-11-17 | $24K | — | Filing → |
| ADAP | BUY | 2020-06-11 | $24K | — | Filing → |